Anvesana is developing therapeutics to treat disorders caused by insufficient protein production. Our core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl, cofounder of Alnylam Pharmaceuticals. Our platform queries mRNA sequence data to identify targetable regions for up-regulating gene expression using anti-sense oligonucleotides. Hundreds of rare genetic diseases are caused by insufficient protein production. Many of these have devastating effects on the affected individual and have no approved disease-modifying therapy.